Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method of treating severe steroid-refractory ulcerative colitis in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a pharmaceutical formulation comprising an antibody, wherein said antibody binds to CD3, wherein said administering reduces the severity of ulcerative colitis symptoms of the patient.

2-3. (cancel)

4. (currently amended) The method according to claim 3, wherein said treatment reduces the Modified Truelove and Witts Severity Index (MTWSI) score or the Mayo Scoring System for Assessment of Ulcerative Colitis Activity (MAYO) score of said patient.

5. (original) The method according to claim 4, wherein said MTWSI score or said MAYO score of said patient is reduced by at least 75%.

6. (original) The method according to claim 1, wherein said treatment causes remission of ulcerative colitis.

7. (original) The method according to claim 6, wherein said remission lasts for at least 90 days

8. (original) The method according to claim 6, wherein said remission is achieved no more than 30 days after said treatment.

9. (cancel)

10. (original) The method according to claim 9, wherein said antibody has a binding affinity for said human CD3 of at least 10^8 M^{-1}.

11. (original) The method according to claim 10, wherein said antibody has a binding affinity for said human CD3 of at least 10^9 M^{-1}.

12. (original) The method according to claim 1, wherein said antibody is a monoclonal antibody.

13. (original) The method according to claim 1, wherein said antibody is a chimeric antibody or a human antibody.

14. (original) The method according to claim 1, wherein said antibody is a humanized antibody.

15. (currently amended) The method according to claim 14, wherein said humanized antibody is a humanized form of a mouse antibody comprising a light chain variable region designated SEQ ID NO:4 and a heavy chain variable region comprising SEQ ID NO:5 ~~M291 antibody~~.

16. (currently amended) The method according to claim [[15]] 1, wherein said humanized ~~M291~~ antibody comprises a mature light chain variable region whose amino acid sequence is residues 21-126 of SEQ ID NO:1, a human kappa constant region, a mature heavy chain variable region whose amino acid sequence is residues 20-139 of SEQ ID NO:2 and a heavy chain constant region whose amino acid sequence is SEQ ID NO:3 ~~is visilizumab~~.

17. (currently amended) The method according to claim 1, wherein said antibody binds to the same epitope as an antibody comprising a mature light chain variable region whose amino acid sequence is residues 21-126 of SEQ ID NO:1, a human kappa constant region, and a mature heavy chain variable region whose amino acid sequence is residues 20-139 of SEQ ID NO:2 and a heavy chain constant region whose amino acid sequence is SEQ ID NO:3 ~~visilizumab~~.

18. (cancel)

19. (currently amended) The method according to claim [[17]] 1, wherein said antibody has CDR regions that have amino acid sequences that are identical to the amino acid sequences of the CDR regions of SEQ ID NOS:1 and 2 ~~visilizumab~~.

20. (original) The method according to claim 1, wherein the pharmaceutical formulation is administered parentally, intravenously, intramuscularly, or subcutaneously.

21-22 (cancel)

23. (original) The method according to claim 20, wherein said therapeutically effective amount is 15 μg/kg or less.

24. (original) The method according to claim 23, wherein said therapeutically effective amount is 10 μg/kg or less.

25. (original) The method according to claim 1, wherein the patient is a human.

26. (previously presented) The method according to claim 1, wherein one or more agents selected from the group consisting of methylprednisolone, hydrocortisone, ondansetron,

acetaminophen, 6-mercaptopurine, and 5-aminosalicylic acid (5-ASA) is/are administered to the patient.

27. (new) The method of claim 23, wherein a course of treatment consists of a single administration of the therapeutically effective amount.

28. (new) The method of claim 23, wherein a course of treatment consists of administration of the therapeutically effective amount on two days.

29. (new) The method of claim 24, wherein a course of treatment consists of a single administration of the therapeutically effective amount.

30. (new) The method of claim 24, wherein a course of treatment consists of administration of the therapeutically effective amount on two days.